Friday, Progenics Pharmaceuticals, Inc. (PGNX) reported a narrower loss for the second quarter, meeting analysts' estimates.
Net loss for the second quarter was $2.37 million or $0.08 per share, narrower than $2.38 million or $0.09 per share last year.
On average, 10 analysts polled by First Call/Thomson Financial expected the company to report loss of $0.08 per share.
Quarterly total net revenues grew to $28.58 million from $25.46 million in the prior-year quarter. Analysts had a consensus revenue estimate of $29.52 million.
Research and development expenditure for the quarter rose to $23.9 million from $22.4 million prior year.
For the quarter, Progenics earned a $15.0 million milestone payment for U.S. Food and Drug Administration (FDA) approval of subcutaneous Relistor.
For the first-half, net loss was $17.8 million or $0.61 per share, wider than net loss of $12.8 million or $0.48 per share prior year same period. Total revenues for the period stood at $43.3 million, up from $43.1 million prior year.
Thursday, PGNX's stock last traded at $15.86 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.